Jan 4, 2019
Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments.
- Intro :10
- Background on Dr. Furie :16
- The interview :56
-
- What advancements in the pathophysiology of lupus are you most excited about? 1:10
- The interferon story 1:23
-
- The interferon story is not finished yet 7:18
- Dendritic cells in lupus patients 7:41
- What is “interferon signature?” 8:07
- Do we see different clinical phenotype in patients with high interferon signature? 9:38
- What’s your opinion on the role of B cells? 10:07
-
- Any other pathophysiology mechanisms being used to target B cells? 13:15
- Are we stretched thin in terms of number of lupus patients in trials? 15:21
-
- How would designating lupus as an orphan disease change the way it’s investigated? 16:40
- What is your main concern regarding study design? 17:37
- Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26
- What’s the expense of cytokine profiling? 22:40
- What excites you the most about the future of lupus research? 23:21
- Thank you, Dr. Furie 24:41
- Recap 24:43
- Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31
We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum.
This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.